Beta Bionics Announces Closing of a $60 Million Series E Financing

Beta Bionics has successfully closed a $60 million Series E financing round, led by Wellington Management, with participation from existing investors including Eventide Asset Management and Sands Capital. The funding will support the commercialization of Beta Bionics' iLet Bionic Pancreas, an autonomous insulin delivery system that simplifies diabetes management by automatically determining insulin doses without the need for carb counting or insulin adjustments. The company aims to improve health outcomes and quality of life for people with diabetes and other glycemic conditions.

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

CytoReason has secured $80 million in funding from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to enhance its disease models and proprietary data, enabling faster and more precise decision-making for R&D leaders in partner companies. The investment will allow CytoReason to expand its model applications, increase its molecular and clinical data, and establish an office in Cambridge, Massachusetts. This funding comes as the company has recently strengthened its partnerships with major pharmaceutical firms, including Pfizer, and now serves six of the world’s top ten pharma companies. CytoReason's technology aids in improving R&D timelines and the probability of technical and regulatory success. With a focus on leveraging AI and computational disease models, CytoReason aims to revolutionize data usage in pharma R&D, ultimately benefiting patient care worldwide.

Glooko scores $100M and appoints new CEO

Glooko, the maker of a digital platform for managing diabetes and other chronic diseases, has secured $100 million in Series F funding and announced Mike Alvarez as the company's newly appointed CEO.  Georgian led the round with participation from Canaan, Health Catalyst Capital, and other investors and business partners. The California-based company will use the funds to scale its product expansion globally. 

Alvarez formerly held the CEO role at Qardio, a remote patient monitoring and healthcare technology company for chronic disease management. Before that, he held leadership positions at medical device maker Medtronic, pharma company Sanofi and St. Jude Medical, which was acquired by Abbott. 

RYSE Asset Management invests in Curio Digital Therapeutics to support the development of new therapeutics for underserved women's mental health conditions

RYSE Asset Management, the healthcare investor supporting innovative early-stage companies transforming lives, announced it has participated in a double digit investment round for Curio Digital Therapeutics Inc., (Curio), an innovative US company treating postpartum depression (PPD) and other underserved women's mental health conditions. Strategic investor ONCE, the nutraceuticals venture capital arm of Otsuka; Bridge Point Capital and Avestria also participated in the round. New Jersey based Curio has received FDA approval for its lead product MamaLift Plus. MamaLift Plus is the women's health first prescription digital therapeutic to receive SaMD Class2 approval. Curio is currently working with health plans, insurers and corporate employee benefit plans in the US and India. They also work at a strategic level with pharma companies and others who seek to engage with Curio's data and underlying connected care platform which spans post-natal depression, fertility and menopause.

Nouvelle levée de fonds de 15 millions d’euros pour Diabeloop qui annonce la nomination de François Miceli au poste de Président et Directeur Général

Diabeloop announced a major step in its growth with a €15 million fundraising round and the appointment of François Miceli as its new President and CEO. The funds will support the company's development, particularly in accelerating revenue growth for its DBLG1 closed-loop system and preparing the launch of DBLG2, a smartphone-integrated algorithm compatible with both Android and iOS.

GLUCOTRACK ANNOUNCES NEW FUNDING FOR DEVELOPMENT OF ITS CONTINUOUS BLOOD GLUCOSE MONITOR

Glucotrack, Inc. has secured $4 million in funding from its major shareholder, John Ballantyne, to support its upcoming First in Human clinical trial for its Continuous Blood Glucose Monitor (CBGM) technology. CEO Paul V. Goode noted significant progress in the technology's development and expressed confidence in its potential impact on the diabetes market. Ballantyne praised the company's advancements and leadership, emphasizing the potential for significant clinical and shareholder value.

Huma completes Series D with total financing of over $80m as it launches Huma Cloud Platform

 Huma Therapeutics Limited is announcing the completion of its Series D funding round to help cut that time down to days as it launches the Huma Cloud Platform. The platform offers no-code configuration of regulated disease management tools for any therapeutic area, a library of pre-built modules and device connectivity capabilities, a cloud-agnostic framework for flexible hosting, readily available APIs and integration capabilities, the ability to host and deploy diagnostic and predictive AI algorithms, a marketplace, and more to advance digital-first care and research. The Series D funding round, alongside investments from leading industry partners since its Series C round, created a total issuance of shares by Huma of over $80m. With this round, Huma has now raised over $300m. The Series D saw the participation of new and existing strategic and financial investors, including AstraZeneca, Hat Technology Fund 4 by HAT SGR, HV Fund by Hitachi Ventures and Leaps by Bayer and others.

Thyme Care Closes $95M Series C To Fuel Cancer Care Affordability

Thyme Care, a value-based cancer care enabler, announced the close of a $95M capital raise. With $55M in equity funding, Thyme Care welcomes new investor Concord Health Partners with participation from all existing investors, including CVS Health Ventures, Town Hall Ventures, a16z Bio + Health, AlleyCorp, Echo Health Ventures, Frist Cressey Ventures, and Foresite Capital. Banc of California will provide an additional $40M in debt financing, bringing Thyme Care's total amount raised to date to $178M. Thyme Care's suite of services, including its 24/7 specialized cancer care navigation services, robust technology and data insights, and provider-led therapeutic interventions enable a more seamless patient experience and drive sustainability across the ecosystem.

Sword Health Introduces Phoenix, the First AI Care Specialist and Raises $130 Million in a Mix of Primary and Secondary Sale

Sword Health has announced a $130 million financing round, raising its total funding to $340 million and valuing the company at $3 billion, a 50% increase from its Series D valuation. This funding round includes primary and secondary sales to provide liquidity to employees and early investors. The company also introduced Phoenix, an AI Care Specialist that offers real-time guidance and feedback to patients during their sessions through natural conversation. Phoenix will first be integrated into Sword's solutions Thrive for physical pain and Bloom for women's pelvic health.

Biosensor technology company Allez Health secures $60M

Allez Health, a California-based company formerly known as Zense-Life, has secured $60 million in Series A+ financing, led by Osang Healthcare with participation from existing investors. Allez Health specializes in continuous glucose monitoring (CGM) biosensor technology aimed at enhancing patient performance through comprehensive health data analysis. The company’s leadership team includes former Dexcom executives, with CEO Leif Bowman, CTO Robert Boock, and Chief Science Officer Ted Zhang all having significant experience from Dexcom. The funding will support operations, regulatory filings, manufacturing scaling, and clinical trials.